Background and Organization (Details) - USD ($) |
12 Months Ended | |||
|---|---|---|---|---|
Sep. 19, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 21, 2021 |
|
| Subsidiary, Sale of Stock [Line Items] | ||||
| Share price | $ 0.50 | |||
| Gross proceeds | $ 5,000,000 | |||
| Net proceeds | $ 4,490,605 | |||
| Warrants exercise price percentage of IPO Price | 125.00% | |||
| Warrants to purchase shares | 500,000 | 172,500 | ||
| Warrants exercise price | $ 0.625 | $ 12.50 | ||
| Net loss | $ 12,247,834 | $ 15,960,268 | ||
| Net cash used in operating activities | 11,467,797 | 15,689,578 | ||
| Accumulated deficit | $ 56,173,207 | $ 43,925,373 | ||
| Minimum | ||||
| Subsidiary, Sale of Stock [Line Items] | ||||
| Period in which the company has to raise additional capital to complete clinical development | 13 months | |||
| Maximum | ||||
| Subsidiary, Sale of Stock [Line Items] | ||||
| Period in which the company has to raise additional capital to complete clinical development | 18 months | |||
| IPO | Maximum | ||||
| Subsidiary, Sale of Stock [Line Items] | ||||
| Shares issued | 10,000,000 | |||
| X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash inflow from the additional capital contribution to the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Cash received on stock transaction after deduction of issuance costs. No definition available.
|
| X | ||||||||||
- Definition Price of a single share of a number of saleable stocks of a company. No definition available.
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The period in which the company has to raise additional capital to complete clinical development. No definition available.
|
| X | ||||||||||
- Definition Warrants exercise price as percentage of initial public offering price. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|